The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT.
Chemoradiotherapy
Eosinophils
HPV
Oropharyngeal cancer
Prognostic factor
Squamous cell anal cancer
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
02
07
2022
medline:
18
8
2023
pubmed:
2
8
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
Anal squamous cell carcinoma (SCC) and oropharyngeal cancer (OPC) are rare tumors associated with HPV infection. Bioumoral predictors of response to chemoradiation (CT-RT) are lacking in these settings. With the aim to find new biomarkers, we investigated the role of eosinophils in both HPV-positive anal SCC and HPV-related oropharyngeal cancer (OPC). We retrieved clinical and laboratory data of patients with HPV-positive anal SCC treated with CT-RT in 5 institutions, and patients with locally advanced OPC SCC treated with CT-RT in 2 institutions. We examined the association between baseline eosinophil count (the best cutoff has been evaluated by ROC curve analysis: 100 × 10^9/L) and disease-free survival (DFS). Unadjusted and adjusted hazard ratios by baseline characteristics were calculated using the Cox proportional hazards model. Three hundred four patients with HPV-positive anal SCCs and 168 patients with OPCs (122 HPV-positive, 46 HPV-negative diseases) were analyzed. In anal SCC, low eosinophil count (< 100 × 10^9/L) correlates to a better DFS (HR = 0.59; p = 0.0392); likewise, in HPV-positive OPC, low eosinophil count correlates to a better DFS (HR = 0.50; p = 0.0428). In HPV-negative OPC, low eosinophil count confers worse DFS compared to high eosinophil count (HR = 3.53; p = 0.0098). After adjustment for age and sex, eosinophils were confirmed to be independent prognostic factors for DFS (HR = 4.55; p = 0.0139). Eosinophil count could be used as a prognostic factor in anal HPV-positive SCC. The worse prognosis showed in HPV-positive patients with high eosinophil count is likely to derive from an unfavorable interaction between the HPV-induced immunomodulation and eosinophils, which may hamper the curative effect of RT.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Anal squamous cell carcinoma (SCC) and oropharyngeal cancer (OPC) are rare tumors associated with HPV infection. Bioumoral predictors of response to chemoradiation (CT-RT) are lacking in these settings. With the aim to find new biomarkers, we investigated the role of eosinophils in both HPV-positive anal SCC and HPV-related oropharyngeal cancer (OPC).
METHODS
METHODS
We retrieved clinical and laboratory data of patients with HPV-positive anal SCC treated with CT-RT in 5 institutions, and patients with locally advanced OPC SCC treated with CT-RT in 2 institutions. We examined the association between baseline eosinophil count (the best cutoff has been evaluated by ROC curve analysis: 100 × 10^9/L) and disease-free survival (DFS). Unadjusted and adjusted hazard ratios by baseline characteristics were calculated using the Cox proportional hazards model.
RESULTS
RESULTS
Three hundred four patients with HPV-positive anal SCCs and 168 patients with OPCs (122 HPV-positive, 46 HPV-negative diseases) were analyzed. In anal SCC, low eosinophil count (< 100 × 10^9/L) correlates to a better DFS (HR = 0.59; p = 0.0392); likewise, in HPV-positive OPC, low eosinophil count correlates to a better DFS (HR = 0.50; p = 0.0428). In HPV-negative OPC, low eosinophil count confers worse DFS compared to high eosinophil count (HR = 3.53; p = 0.0098). After adjustment for age and sex, eosinophils were confirmed to be independent prognostic factors for DFS (HR = 4.55; p = 0.0139).
CONCLUSION
CONCLUSIONS
Eosinophil count could be used as a prognostic factor in anal HPV-positive SCC. The worse prognosis showed in HPV-positive patients with high eosinophil count is likely to derive from an unfavorable interaction between the HPV-induced immunomodulation and eosinophils, which may hamper the curative effect of RT.
Identifiants
pubmed: 35915202
doi: 10.1007/s12029-022-00850-y
pii: 10.1007/s12029-022-00850-y
pmc: PMC9342937
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
662-671Informations de copyright
© 2022. The Author(s).
Références
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
J Clin Oncol. 1996 Sep;14(9):2527-39
pubmed: 8823332
N Engl J Med. 1997 Nov 6;337(19):1350-8
pubmed: 9358129
Radiother Oncol. 2017 Jan;122(1):137-145
pubmed: 28024835
Viruses. 2017 Aug 18;9(8):
pubmed: 28820495
Clin Cancer Res. 2008 Aug 1;14(15):4705-12
pubmed: 18676738
Cell Growth Differ. 1996 Dec;7(12):1661-9
pubmed: 8959334
Cancer Res. 2011 Feb 1;71(3):1187-95
pubmed: 21148070
Int J Cancer. 2014 May 1;134(9):2061-73
pubmed: 24136650
Future Oncol. 2019 Oct;15(30):3467-3481
pubmed: 31580723
Open Virol J. 2012;6:216-31
pubmed: 23341857
Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10
pubmed: 16949995
Cancer Treat Rev. 2015 Dec;41(10):844-52
pubmed: 26476574
J Immunol. 2009 Oct 15;183(8):5023-31
pubmed: 19794066
PLoS One. 2011 Mar 14;6(3):e17848
pubmed: 21423754
Cancer Manag Res. 2020 Jan 23;12:541
pubmed: 32021463
Lancet Oncol. 2013 May;14(6):516-24
pubmed: 23578724
Cancer Res. 2009 Nov 15;69(22):8718-25
pubmed: 19887612
Lancet. 1996 Oct 19;348(9034):1049-54
pubmed: 8874455
PLoS One. 2012;7(3):e34366
pubmed: 22470562
J Exp Med. 2000 Aug 21;192(4):565-70
pubmed: 10952726
Oncotarget. 2016 Oct 11;7(41):67142-67149
pubmed: 27613839
Cancer. 2004 Jul 15;101(2):270-80
pubmed: 15241823
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
Clin Transl Oncol. 2019 Jul;21(7):836-844
pubmed: 30470994
Viral Immunol. 2017 Mar;30(2):98-105
pubmed: 28151089
Br J Haematol. 2018 Jun;181(6):837-840
pubmed: 28439879
Radiother Oncol. 2013 May;107(2):242-6
pubmed: 23602369
Curr Mol Med. 2008 Aug;8(5):350-8
pubmed: 18691061
Cancer Med. 2018 Mar;7(3):690-697
pubmed: 29468834
Asia Pac J Clin Oncol. 2018 Oct;14(5):e243-e251
pubmed: 29532611
J Virol. 2011 Nov;85(21):11372-80
pubmed: 21849431
Sci Rep. 2012;2:515
pubmed: 22808421
Immunol Cell Biol. 2010 Mar-Apr;88(3):250-6
pubmed: 20065995
Cancer. 1983 Jul 1;52(1):126-30
pubmed: 6850535
J Virol. 2000 May;74(9):4174-82
pubmed: 10756030
Nat Immunol. 2019 Sep;20(9):1220-1230
pubmed: 31285626
Radiat Oncol. 2018 May 2;13(1):83
pubmed: 29720197
Int J Colorectal Dis. 2019 Mar;34(3):519-525
pubmed: 30617412
Cancer Manag Res. 2018 Dec 24;11:191-199
pubmed: 30636893
J Clin Oncol. 1997 May;15(5):2040-9
pubmed: 9164216
J Virol. 2011 Sep;85(17):8852-62
pubmed: 21697473
JAMA. 2008 Apr 23;299(16):1914-21
pubmed: 18430910
Virus Res. 2017 Mar 2;231:56-75
pubmed: 27818212
World J Clin Oncol. 2014 Oct 10;5(4):753-63
pubmed: 25302175
Radiother Oncol. 2010 Jan;94(1):30-5
pubmed: 19910068
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
APMIS. 2010 Jun;118(6-7):510-9
pubmed: 20553531
Cytokine. 2011 Dec;56(3):798-803
pubmed: 22015106
Am J Cancer Res. 2015 Feb 15;5(3):1017-31
pubmed: 26045983
Leuk Res. 2007 Jul;31(7):915-20
pubmed: 17123603
Cancer Manag Res. 2019 Apr 26;11:3631-3642
pubmed: 31118786
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Cancer Res. 2013 Aug 1;73(15):4791-800
pubmed: 23749640
PLoS One. 2014 Oct 01;9(10):e109018
pubmed: 25272036
J Otolaryngol Head Neck Surg. 2018 Sep 21;47(1):59
pubmed: 30241572
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
J Virol. 2015 Nov;89(22):11396-405
pubmed: 26339055
J Thorac Oncol. 2018 Jan;13(1):97-105
pubmed: 29170120
Int J Mol Med. 2010 Jul;26(1):51-6
pubmed: 20514422
J Immunother Cancer. 2018 Oct 17;6(1):107
pubmed: 30333065
Blood. 2007 Sep 1;110(5):1578-86
pubmed: 17495130
Clin Transl Oncol. 2020 Jan;22(1):81-90
pubmed: 31004253
Oncotarget. 2014 Jan 30;5(2):403-16
pubmed: 24480782
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690